Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Not yet recruiting × alectinib × Clear all

Phase

Phase NA 1 Phase 2 1

Status

Recruiting 10 Completed 4 Active not recruiting 4 Unknown 1 Terminated 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Interventions

Cisplatin 66 Carboplatin 63 Oxaliplatin 50 Bevacizumab 50 Capecitabine 46 Radiotherapy 45 Drug Therapy 45 tislelizumab 43 Gemcitabine 42 pembrolizumab 41 Paclitaxel 41 toripalimab 40 sintilimab 32 Cyclophosphamide 31 130-nm albumin-bound paclitaxel 28 Specimen Handling 26 anlotinib 25 Surgical Procedures, Operative 24 Pemetrexed 23 Docetaxel 23 Injections 22 lenvatinib 21 Fluorouracil 21 apatinib 19 Etoposide 19 Immune Checkpoint Inhibitors 17 cemiplimab 16 S 1 (combination) 16 Radiosurgery 16 Immunotherapy 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡